TimesSquare Capital Management LLC Has $33.28 Million Stock Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

TimesSquare Capital Management LLC lifted its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 9.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 848,850 shares of the biopharmaceutical company's stock after buying an additional 70,557 shares during the period. TimesSquare Capital Management LLC owned about 1.11% of Xenon Pharmaceuticals worth $33,275,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Blue Trust Inc. boosted its position in shares of Xenon Pharmaceuticals by 174.7% during the third quarter. Blue Trust Inc. now owns 1,008 shares of the biopharmaceutical company's stock worth $39,000 after buying an additional 641 shares during the period. Avior Wealth Management LLC bought a new stake in Xenon Pharmaceuticals during the fourth quarter worth about $101,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in Xenon Pharmaceuticals by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,740 shares of the biopharmaceutical company's stock worth $106,000 after acquiring an additional 487 shares in the last quarter. KBC Group NV raised its holdings in Xenon Pharmaceuticals by 39.8% during the fourth quarter. KBC Group NV now owns 2,742 shares of the biopharmaceutical company's stock worth $107,000 after acquiring an additional 780 shares in the last quarter. Finally, HighMark Wealth Management LLC raised its holdings in Xenon Pharmaceuticals by 22.0% during the fourth quarter. HighMark Wealth Management LLC now owns 6,100 shares of the biopharmaceutical company's stock worth $239,000 after acquiring an additional 1,100 shares in the last quarter. 95.45% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on XENE shares. HC Wainwright reiterated a "buy" rating and set a $53.00 target price on shares of Xenon Pharmaceuticals in a report on Thursday, December 12th. Deutsche Bank Aktiengesellschaft started coverage on Xenon Pharmaceuticals in a research note on Tuesday, February 11th. They issued a "buy" rating and a $67.00 price objective on the stock. Finally, Needham & Company LLC restated a "buy" rating and issued a $60.00 price objective on shares of Xenon Pharmaceuticals in a research note on Wednesday, November 13th. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $57.38.

Insider Activity

In related news, CFO Sherry Aulin sold 18,709 shares of the stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $41.21, for a total transaction of $770,997.89. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Ian Mortimer sold 16,315 shares of the stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $40.50, for a total value of $660,757.50. Following the sale, the chief executive officer now directly owns 31,302 shares in the company, valued at $1,267,731. This represents a 34.26 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 57,492 shares of company stock valued at $2,334,969. 5.52% of the stock is owned by insiders.

Xenon Pharmaceuticals Stock Up 0.9 %

Shares of Xenon Pharmaceuticals stock traded up $0.35 on Friday, hitting $39.73. The stock had a trading volume of 234,719 shares, compared to its average volume of 420,733. Xenon Pharmaceuticals Inc. has a twelve month low of $35.53 and a twelve month high of $50.99. The business's 50 day moving average is $39.45 and its two-hundred day moving average is $40.40. The stock has a market cap of $3.03 billion, a price-to-earnings ratio of -14.09 and a beta of 1.20.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.